Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Health Canada Accepts Mitsubishi Tanabe’s Plant-Derived Flu Vaccine for Review
October 3, 2019
- Nippon Shinyaku Seeks US Approval for DMD Therapy Viltolarsen
October 3, 2019
- Asahi Kasei Sues Endo over Xiaflex Supply Halt
October 2, 2019
- Axcelead Gets Its Hands on PassPort’s Transdermal Drug Delivery Technology
October 2, 2019
- Taisho Grabs Japan Rights to Moberg’s Topical Onychomycosis Drug
October 2, 2019
- Nippon Zoki to Develop Its 1st Biologic by Licensing Bone Forming Promoting Drug from South Korean Biotech
October 2, 2019
- Eisai, US Merck Present Final PII Results for Lenvima/Keytruda Combo for Endometrial Cancer
October 2, 2019
- Tsuyoshi Mitsuhashi Appointed as New President of Konica Minolta Precision Medicine
October 2, 2019
- Opdivo Significantly Extends OS against Chemo in Esophageal Cancer
October 2, 2019
- Takara Bio Drops Oncolytic Virus Filing for Melanoma in Japan
October 1, 2019
- ADC-Keytruda Combo Shows ORR of 71% in 1st Line Bladder Cancer: Astellas/Seattle Genetics
October 1, 2019
- Avanir’s AVP-786 Misses Goals in PIII for Moderate-to-Severe Agitation in AD Patients
October 1, 2019
- Eisai, Nichi-Iko Team Up for Generic Business in China
October 1, 2019
- AZ to Focus on Asthma-COPD Overlap in Marketing Triple-Combo Therapy Breztri, Will Help GPs Make Diagnosis
September 30, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March
September 27, 2019
- Meiji Seika’s Korean JV Passes GMP Inspection by PMDA, Preparing for Contract Production of Nesp Biosimilar
September 27, 2019
- Otsuka Files for Abilify Once-Monthly Injection for Bipolar Disorder in Japan
September 27, 2019
- Takeda’s Sakigake-Designated Narcolepsy Drug Prolongs Sleep Latency in PI
September 27, 2019
- Entyvio Shows Superiority to Humira in Clinical Remission in Comparison Study: Takeda
September 27, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…